Wegovy Faces Legal Battle, Oral Approval Expands as Obesity Drug Market Intensifies Globally

# Wegovy News Roundup: Novo Nordisk vs. Eli Lilly Lawsuit, Oral Pill Approval & New Safety Concerns **Meta Description:** Wegovy makes headlines with a Novo Nordisk-Eli Lilly lawsuit, EU approval of oral Wegovy, Medicare access pilot, and new semaglutide safety data. Listen now. ## Episode Description Wegovy is dominating health and pharma news this week, and this episode breaks down everything you need to know. We cover Novo Nordisk's lawsuit against Eli Lilly over alleged false advertising for Zepbound and Mounjaro, backed by fresh data showing Wegovy HD's impressive 19% average weight loss results from the STEP UP study. We also dive into the landmark European Commission approval of oral Wegovy, now available across 27 EU member states plus Norway, Iceland, and Liechtenstein—marking a major shift from injectable-only treatment to a needle-free option for millions of patients battling obesity. This episode explores the expanding semaglutide safety conversation, including new research on stomach paralysis, sudden vision loss, and a rare "eye stroke" condition linked to Wegovy use. We also examine encouraging findings on semaglutide's effectiveness in adults over 65, who saw over 15% body weight reduction with improved cardiometabolic health. On the access front, we discuss the new CMS pilot program offering Wegovy and competing GLP-1 drugs at $50/month for eligible Medicare and Medicaid beneficiaries, plus updates confirming the injectable semaglutide shortage has finally been resolved. Whether you're a patient, healthcare provider, investor, or just following the GLP-1 weight loss drug wars, this episode delivers the latest on Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai